The Rise of Genetically Modified Babies in Silicon Valley
Some biotech companies in Silicon Valley are reportedly involved in controversial efforts to create genetically modified babies, according to recent reports. These firms are conducting embryo editing experiments in countries where such practices are permitted, aiming to develop technology that could result in babies with higher IQs and fewer genetic diseases. This kind of work is strictly illegal in the United States and many other nations.
One such company, Preventive, a Silicon Valley startup, is allegedly conducting these experiments in places like the United Arab Emirates (UAE), where embryo editing is allowed. The company has received funding from notable figures, including Sam Altman, CEO of OpenAI, his partner Oliver Mulherin, and Brian Armstrong, co-founder and CEO of Coinbase.
The report claims to have obtained internal communications that detail these activities, with an anonymous source stating, “Company executives are already discussing embryo editing experiments for a couple suffering from genetic diseases.”
Preventive has denied the allegations, with CEO Lucas Harrington stating, “We are not currently conducting embryo editing experiments” and adding, “We have no intention of proceeding with clinical trials unless safety is proven.” However, investor Brian Armstrong responded to the report on social media, saying, “Over 300 million people worldwide live with genetic diseases. Correcting these at an early stage, such as the embryonic phase when cell count is low, is far easier than treating them after they progress.” Mulherin also released a statement, saying, “We are interested in research that helps people avoid diseases,” and noted, “Sam Altman supports this as well.”
Ethical and Scientific Concerns
Currently, approved gene-editing technologies focus on modifying DNA to treat diseases after birth. Editing genes at the embryonic stage—before a person becomes a fetus—remains highly controversial. In 2018, Chinese scientist He Jiankui was sentenced to three years in prison after announcing he had genetically modified the embryos of three babies to grant them immunity to HIV.
Beyond Preventive, other biotech firms are also exploring the possibility of genetically modified babies through embryo editing. Companies like Manhattan Genomics and Bootstrap Bio are reportedly researching methods to produce babies with stronger hearts, lower cholesterol, and robust bones in regions with lax regulations, such as Honduras. Although still in early stages, these efforts raise significant ethical concerns.
Polygenic Screening and Genetic Prediction
Firms like Orchid and Genomic Prediction offer “polygenic screening” tools. These extract DNA from embryos and use statistical algorithms to predict traits or disease risks the child may have, enabling parents to select embryos for implantation. Companies such as HeraBiotech and Nucleus Genomics claim their DNA analysis can forecast a child’s intelligence, height, and other characteristics.
These firms have reportedly received investments from Silicon Valley figures, including Peter Thiel, Alexis Ohanian, and Brian Armstrong of Coinbase. Elon Musk is also said to have used Orchid’s genetic screening technology to evaluate embryos for his twins with former Neuralink executive Shivon Zilis. At the time, Musk stated, “Genetic technology will accelerate human evolution,” referencing the sci-fi film ‘Gattaca’.
Warnings from the Scientific Community
The scientific community has raised alarms over these developments. Critics warn that the technology could be misused for “baby enhancement” rather than disease treatment, potentially reviving eugenics. Fyodor Urnov, of UC Berkeley’s Innovative Genomics Institute, said, “Private capital treating life as an experiment sets a dangerous precedent.” Marcel Chedas, a senior physician at UC’s IVF Center, added, “Babies should be born as they are. Artificially altering this is not only impossible but extremely dangerous.”
As the debate continues, the line between medical advancement and ethical transgression remains blurred. The potential for misuse of such powerful technology underscores the need for strict oversight and global cooperation to ensure it is used responsibly.